Le Lézard
Classified in: Health, Science and technology
Subject: PER

Michael Brozino Joins Maverick Medical AI as Co-Founder and Chief Commercial Officer to Bring Clinical AI Cognitiontm Tech to Market


TEL AVIV, Israel, Aug. 5, 2020 /PRNewswire/ -- Maverick Medical AI announced today that Michael Brozino, a veteran healthcare technology executive, has joined as Co-Founder and Chief Commercial Officer. Brozino will be responsible for driving commercial growth and US expansion of the company focused on improving clinical data quality and analysis through its Clinical AI Cognitiontm platform.

Brozino adds more than two decades of senior leadership in healthcare technology to the Maverick team, which includes: partner at TechCXO; fractional CEO and COO at several health technology companies; serving as CEO of iScRipt; serving as President and CEO of simplifyMD; and a variety of senior leadership positions across a number of McKesson's healthcare technology business units.

Brozino is a graduate of Penn State with B.S. in economics and bioscience.

"I've spent decades working with many technology solutions to complex health system problems, and I've rarely encountered technology as promising as Maverick's Clinical AI Cognitiontm platform," said Michael Brozino. "While this tool offers the most obvious benefits to those working on risk adjustment for Medicare Advantage, there are countless other applications including clinical data mining and serving as a specialist report assistant."

"Knowing Mike from our time together as executives at McKesson, he was my first call to help us grow Maverick's commercial relationships, particularly in the United States," said Yossi Shahak, Founder and CEO of Maverick Medical AI. "The product we're bringing to the marketplace ? the only AI that understands clinical text as a physician would ? is an invaluable tool for health plans, provider networks, and ACOs."

Brozino's addition to the Maverick team is only the latest exciting news for the company. In late 2019, Maverick entered into its first commercial agreement with leading health management company US Health Systems (USHS). USHS is utilizing Maverick's software for reading primary care physician progress notes and extracting chronic conditions and risk factors with reimbursable value. This followed an initial pilot where Maverick's software was tested and validated by USHS and proven to achieve 98% accuracy on both precision and recall. Maverick's noncommercial relationships include leading health plans and provider organizations.

About

Maverick's Clinical AI Cognitiontm platform is unique in its value-added approach to analyzing patient documentation by mimicking the way specialists read and understand clinical text. The Maverick Platform converts unstructured and fragmented text from patient records to structured information and, in the process, identifies valuable, actionable clinical insights based on an accurate view of patients' true clinical status. Maverick's founding team includes Yossi Shahak and Michael Brozino, former senior executives at McKesson with decades of operations, development, and revenue generation experience between them across large corporations and venture-backed organizations. Maverick is part of The Time incubator in Israel, and affiliated with MassChallenge and StartUp Health.

Yossi Shahak Founder, CEO
[email protected]  
www.maverick-med.com

SOURCE Maverick Medical AI


These press releases may also interest you

at 11:34
At the Annual General Meeting of Vitrolife AB today, the following, amongst other things, was decided: Resolution in accordance with the Board's proposed dividend of SEK 1.00 per share for the financial year 2023. 29 April, 2024 was adopted as the...

at 11:25
TimelyCare, higher education's most trusted virtual health and well-being provider, has earned recognition as one of the World's Best Digital Health Companies by Newsweek, and has been awarded five Top Workplaces Awards for culture excellence....

at 11:16
Avanos Medical, Inc. will webcast its conference call discussing financial results and business highlights for the first quarter 2024 on Thursday, May 2 at 9 a.m., ET. The company will issue a news release detailing its results before the market...

at 11:15
Beijing Avistone Biotechnology Co., Ltd. (also referred to as Avistone Biotechnology or Avistone), an innovative biotechnology company focused on precision oncology therapeutics, announced the approval to expand the use of vebreltinib (also referred...

at 11:10
Through its 2030 Strategic Plan, NJII plans to double the size of the organization and to exceed $70M revenue as it rolls out various new initiatives focused on accelerating technology translation, spurring innovation and upskilling workers. As...

at 11:09
ScreenPoint Medical, today announced a significant transition in its leadership as Mark Koeniguer, the current CEO, steps down from his position. Mark served as CEO since 2022 and was instrumental in ScreenPoint's commercial growth and success over...



News published on and distributed by: